An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Charles River’s CSO Julie Frearson outlines the FDA’s planned transition away from animal testing, changing attitudes to artificial intelligence, and the move to New Alternative Methods.
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
EY's Arda Ural joins In Vivo to discuss the long-awaited recovery in biotech IPOs, the evolving capital markets landscape and how tariffs and TrumpRx are reshaping biopharma supply chains.
Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
